Abstract:Abstract Inflammatory bowel disease (IBD) is characterized symptomatically by chronic inflammation in the colonic tract. Despite the increased understanding of the physiological symptoms of Crohn’s Disease, and IBD in general, there have been no significant breakthroughs in understanding its etiology or improving treatment. As such, there is an urgent need for efficacious therapies that are aimed specifically at preventing or curing IBD. Bolstering the need for better therapies is the fact that patients with IBD have increased risk of developing intestinal cancers. One of the pathological traits of IBD that heightens the risk of cancer is the increased level of angiogenesis that accompanies the inflammation. As the biological processes of angiogenesis and inflammation are intricately linked, we believe increasing the levels of thrombospondin-1 (TSP-1), an anti-angiogenic and anti-inflammatory protein, can reprogram immune and inflammatory cells to inhibit angiogenesis and induce the resolution of inflammation. Vigeo has developed VT1021 which stimulates the expression of TSP-1 in inflammatory myeloid derived suppressor cells (MDSCs) systemically. VT1021 achieved proof of concept in a Phase 1/2 clinical trial with multiple cohorts and is currently in Phase 2/3 trials for oncology indications. IBD patients have increased MDSCs in both lesions and peripheral blood. MDSCs are genomically stable and not mutated in IBD patients and thus represent ideal therapeutic targets. Two dextran sulfate sodium (DSS)-induced colitis models were used to evaluate the pre-clinical efficacy of VT1021. In the preventative model, mice were treated with 4% DSS from Day 0 to Day 6 and either saline or VT1021 from Day 0 to Day 8, then sacrificed on Day 8 to collect colon tissue and plasma samples. In the rescue model, mice were treated with 4% DSS from Day 0 to Day 4, then treated with either saline, VT1021 (25, 50, 100 mg/kg) or anti-TNFa from Day 5 to Day 10. Mice were sacrificed on Day 11; colon tissue and plasma samples were collected. In both models, VT1021 treatment significantly prevented the mouse weight loss and bloody stool compared to the saline treatment. VT1021 treatment also decreased the colon inflammation by the measurement of both plasma myeloperoxidase (MPO) level and colon tissue histopathology score. Immunohistochemistry staining of colon tissue samples confirmed that VT1021 treatment stimulated TSP-1 expression in the MDSCs. Altogether, these findings show that VT1021 treatment has equivalent efficacy to anti-TNFa treatment, while significantly reducing damage to colon tissue. We believe VT1021 will show significantly greater efficacy in patients with longer term use, while avoiding the systemic deleterious side effects common to current approved therapies.

Inhibitory effects of an orally active small molecule alpha4beta1/alpha4beta7 integrin antagonist, TR-728, on TNBS-induced colitis in rats

A novel diamino-pyridine derivative (IS-741) attenuates rat ileitis induced by trinitrobenzene sulfonic acid

Blockade of Complement Activation Product C5a Activity Using Specific Antibody Attenuates Intestinal Damage in Trinitrobenzene Sulfonic Acid Induced Model of Colitis

P131 Therapeutic effects of KPG-818 in a trinitrobenzene sulfonic acid - induced mouse Crohn's/Ulcerative Colitis model

Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis.

Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease

Effects of Recombinant Human Intestinal Trefoil Factor on Trinitrobenzene Sulphonic Acid Induced Colitis in Rats

Resatorvid (TAK-242) Ameliorates Ulcerative Colitis by Modulating Macrophage Polarization and T Helper Cell Balance Via TLR4/JAK2/STAT3 Signaling Pathway

Therapeutic Potential of Triptolide as an Anti-Inflammatory Agent in Dextran Sulfate Sodium-Induced Murine Experimental Colitis

S1331 Colonic Bioactivation and Potent TNFa Inhibition of PALI-2108 in Human ex-vivo Studies: A Promising PDE4 Inhibitor Prodrug for the Oral Treatment of Ulcerative Colitis

The Effects of Rheum Tanguticum Polysaccharide on the Polarization of Th1 and Th2 Cells in TNBS-induced Colitis in Murine

SPH7854, a gut-limited RORγt antagonist, ameliorates TNBS-induced experimental colitis in rat

P098 Novel drug candidate for the treatment of Inflammatory Bowel Disease with unique mechanisms of action

P587 Development and Characterization of a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting Integrin ɑ4β7 for the Treatment of IBD

TLR4 monoclonal antibody blockade suppresses dextran-sulfate-sodium-induced colitis in mice.

P143 Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitis

EVALUATING THE PRE-CLINICAL EFFICACY OF VT1021 (A CLINICAL STAGE DRUG CANDIDATE) IN MULTIPLE EXPERIMENTAL MODELS OF INFLAMMATORY BOWEL DISEASE

[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins]

Discovery of First-in-Class TAK1-MKK3 Protein-Protein Interaction (PPI) Inhibitor (R)-STU104 for the Treatment of Ulcerative Colitis Through Modulating TNF-α Production.

Tripterygium wilfordii Polyglycoside Ameliorated TNBS-Induced Colitis in Rats via Regulating Th17/Treg Balance in Intestinal Mucosa

Combined blockade of α4β7 and αEβ7 integrins leads to a greater reduction of gut proinflammatory T lymphocytes over either pathway alone